NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Pomalyst® (pomalidomide): New important advice- Hepatitis B Virus status to be established before initiating treatment with pomalidomide

User Rating: 3 / 5

Star ActiveStar ActiveStar ActiveStar InactiveStar Inactive
 

Date: 19 January 2017

 

Description:

Reactivation of hepatitis B has been reported rarely following treatment with pomalidomide plus dexamethasone in patients previously infected with the hepatitis B virus (HBV). HBV status should be established before treatment with pomalidomide is initiated. A Direct Healthcare Professional Communication (DHPC) has been issued by Celgene Sdn. Bhd. in agreement with NPRA to highlight this information. Please refer to this DHPC for further information.

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Friday 06 December 2024, 15:23:03.

Search

Main Menu English